AIG
TCRR

American International Group’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

American International Group’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,143
Closed -$42K – 3353
2022
Q1 		$42K Sell
15,143
-1,067
-7% -$3.36K ﹤0.01% 2905
2021
Q4 		$76K Sell
16,210
-485
-3% -$3.03K ﹤0.01% 2831
2021
Q3 		$142K Sell
16,695
-397
-2% -$5.61K ﹤0.01% 2627
2021
Q2 		$280 Buy
17,092
+222
+1% +$4.48K ﹤0.01% 2295
2021
Q1 		$372 Buy
16,870
+2,102
+14% +$57.3K ﹤0.01% 2006
2020
Q4 		$457 Sell
14,768
-423
-3% -$10.7K ﹤0.01% 1811
2020
Q3 		$309K Buy
15,191
+5,229
+52% +$91.8K ﹤0.01% 1862
2020
Q2 		$153K Buy
9,962
+3,028
+44% +$34.9K ﹤0.01% 2285
2020
Q1 		$54K Sell
6,934
-401
-5% -$4.91K ﹤0.01% 2649
2019
Q4 		$105K Sell
7,335
-62
-0.8% -$959 ﹤0.01% 2600
2019
Q3 		$111K Buy
7,397
+6,268
+555% +$97.6K ﹤0.01% 2546
2019
Q2 		$16K Buy
+1,129
New +$18K ﹤0.01% 3068

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

American International Group's TCRR Position: Q2 2022 in Review

American International Group sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2022, closing a stake of 15,143 shares — an estimated $42K sold.

American International Group first reported a position in TCRR in Q2 2019 and held it in 12 quarters. The position peaked at $309K in Q3 2020. 83 funds tracked by Wall St. Rank hold TCRR as of Q2 2022.

  • American International Group reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • American International Group sold 15,143 TCR2 Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $42K.
  • American International Group first reported a position in TCR2 Therapeutics Inc. Common Stock in Q2 2019 and held it in 12 quarters.
  • American International Group's TCR2 Therapeutics Inc. Common Stock position peaked at $309K in Q3 2020.
  • 83 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2022.

Based on American International Group's 13F filing for Q2 2022, filed 12 Aug 2022.